Associated factors of co‐existent pulmonary tuberculosis and lung cancer: A case‐control study

Zheng, Lijun; Yin, Jinfeng; Si-yi, Wang; Jiang, Hui; Hu, Puqi; Kang, Ziqing; Lv, Pingxin; Liu, Weimin; Cai, Chao

doi:10.1111/eci.13432

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been rare reports on the coexistence of lung cancer and pulmonary TB in the same lesion, 1–3 while more cases occur in the same or different lobes. 5 , 6 Ashizawa et al reported a patient with a mass in the left lower lobe undergoing the left lower lobectomy. The specimen showed coexistence of adenocarcinoma and tuberculous granuloma.…”

Section: Discussionmentioning

confidence: 99%

Coexistence of Lung Squamous Cell Carcinoma and Pulmonary Tuberculosis Within a Single Lesion: A Case Report

Liang

2021

OTT

View full text Add to dashboard Cite

Pulmonary tuberculosis (TB) and lung cancer are both common diseases with poor prognosis and high mortality worldwide. The coexistence of the two diseases has rarely been reported while their relationship has been noted. Here we describe a patient diagnosed with both TB and squamous cell carcinoma in a single lesion. The patient had a cough for four months and polypnea for two months, with a smoking history of over 40 years. Chest computed tomography (CT) showed a lobular mass in the right hilar region, which was diagnosed as TB by transbronchial lung biopsy. The symptoms and CT findings indicated the possibility of lung cancer. So, the patient underwent a further lung biopsy at the periphery of the mass, which was confirmed as squamous cell carcinoma. This case illuminated that when the mass with cancer-like morphologic features and location instead of typical TB, even the initial pathological result shows TB, coexistence of the diseases should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Coexistence of Lung Squamous Cell Carcinoma and Pulmonary Tuberculosis Within a Single Lesion: A Case Report

Liang

2021

OTT

View full text Add to dashboard Cite

show abstract

“…Despite the good response to systemic chemotherapy in LC patients, the emergence of isolated sites or new foci, especially in typical anatomical sites of TB infection (e.g., upper lobes or apical lower lobes of the lung), should draw attention to the possibility of complicating a TB infection [104]. A previous retrospective study comparing LC patients with and without TB found that LC patients with TB were more likely to have symptoms such as cough, hemoptysis, nocturnal sweating, and more diverse CT findings such as lobar signs of mass, calcified lesions, pleural thickening, and hemorrhagic pleural effusion [105,106]. If these findings are present in LC patients, the possibility of developing TB complications should be considered.…”

Section: Diagnosis Of Tb Complicated By Lc Patientsmentioning

confidence: 99%

Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis

Otoshi,

Ikeda,

Kaneko

et al. 2024

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) patients are often complicated by other respiratory diseases, including interstitial pneumonia (IP), chronic obstructive pulmonary disease (COPD), and pulmonary tuberculosis (TB), and the management of which can be problematic. NSCLC patients with IP sometimes develop fatal acute exacerbation induced by pharmacotherapy, and the establishment of a safe treatment strategy is desirable. For advanced NSCLC with IP, carboplatin plus nanoparticle albumin-bound paclitaxel is a relatively safe and effective first-line treatment option. Although the safety of immune checkpoint inhibitors (ICIs) for these populations remains controversial, ICIs have the potential to provide long-term survival. The severity of COPD is an important prognostic factor in NSCLC patients. Although COPD complications do not necessarily limit treatment options, it is important to select drugs with fewer side effects on the heart and blood vessels as well as the lungs. Active TB is complicated by 2–5% of NSCLC cases during their disease course. Since pharmacotherapy, especially ICIs, reportedly induces the development of TB, the possibility of developing TB should always be kept in mind during NSCLC treatment. To date, there is no coherent review article on NSCLC with these pulmonary complications. This review article summarizes the current evidence and discusses future prospects for treatment strategies for NSCLC patients complicated with IP, severe COPD, and TB.

show abstract

“…Epidemiological studies have revealed that TB is associated with an increased risk of lung cancer [ 6 , 7 ], or the survival and mortality of lung cancer [ 8 – 10 ], especially adenocarcinoma [ 11 ]. Cabrera-Sanchez J et al have demonstrated that patients diagnosed with TB are at an elevated risk of developing lung cancer [ 6 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

The diagnosis interval influences risk factors of mortality in patients with co-existent active tuberculosis and lung cancer: a retrospective study

Xiong,

Xie,

Wang

et al. 2023

BMC Pulm Med

View full text Add to dashboard Cite

Background Previous studies reported that tuberculosis (TB) is associated with an increased risk of lung cancer or the survival and mortality of lung cancer. However, the impact of coexisting TB on the survival of lung cancer patients was controversial. We aimed to identify risk factors on the survival rate of patients with co-existent active TB and lung cancer. Methods One hundred seventy-three patients diagnosed with active TB and lung cancer from January 2016 to August 2021 in Shanghai pulmonary hospital were selected and divided into two groups (≤ 6 months, > 6 months) according to the diagnosis interval between active TB and lung cancer (the order of diagnosis is not considered). The clinical characteristics and survival were analyzed. Univariate and multivariate logistic regression analyses were used to identify the risk factors for overall survival (OS). Results One hundred seventy-three patients were diagnosed with lung cancer and active TB. The study population exhibited a median age of 64 years, with a majority of 81.5% being male, 58.0% of patients had a history of smoking. Among those involved, 93.6% had pulmonary TB, 91.9% were diagnosed with non-small cell lung cancer (NSCLC), 76.9% were Eastern Cooperative Oncology Group (ECOG) 0–2 and 12.7% were ECOG 3–4. We observed better survival in the > 6 months group compared with the ≤ 6 months group (hazard ratio [HR] 0.456, 95% confidence interval [CI]:0.234–0.889, P = 0.017). The 1-, 3-, and 5- year OS rates were 94.2%, 80.3%, and 77.6%, respectively, in the > 6 months group and 88.3%, 63.8%, and 58.5%, respectively, in the ≤ 6 months group. Surgery (HR 0.193, [95% CI, 0.038–0.097]; P = 0.046) and ECOG Performance Status (HR 12.866, [95% CI, 2.730–60.638]; P = 0.001) were independent prognostic factors in the > 6 months group. Conclusions Patients diagnosed with lung cancer and active TB for more than half a year have a significantly better prognosis than those diagnosed within half a year. ECOG Performance Status and surgery might possibly affect the outcomes of patients with co-existent active TB and lung cancer.

show abstract

Associated factors of co‐existent pulmonary tuberculosis and lung cancer: A case‐control study

Cited by 5 publications

References 22 publications

Coexistence of Lung Squamous Cell Carcinoma and Pulmonary Tuberculosis Within a Single Lesion: A Case Report

Coexistence of Lung Squamous Cell Carcinoma and Pulmonary Tuberculosis Within a Single Lesion: A Case Report

Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis

The diagnosis interval influences risk factors of mortality in patients with co-existent active tuberculosis and lung cancer: a retrospective study

Contact Info

Product

Resources

About